Harmony Biosciences’ $60 million bet on a once-failed Fragile X candidate has gone off the rails. Two years after picking up ZYN002 despite a midphase flop, the biotech has reported that a ...
Chinese humanoid company X Square Robot secured $100 million in an A+ round of funding led by Alibaba Cloud and CAS Investment on Monday. The firm’s Chief Operating Officer, Yang Qian, said the ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Harmony Biosciences faces a ...
X Square Robot, a Shenzhen-based humanoid startup, secured approximately $100 million in funding led by Alibaba Group Holding (NYSE:BABA) through Alibaba Cloud in a deal that strengthens the company's ...
Harmony Biosciences Holdings, Inc. is downgraded from Buy to Hold after a failed Phase 3 trial for ZYN002 in Fragile X syndrome. HRMY's pipeline setback and sNDA rejection raise concerns about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback